RIBOMIC Inc. announced that the first dose of RBM-007 (anti-FGF2 aptamer) was administered to a pediatric patient with Achondroplasia in the early phase II study to investigate the efficacy and safety of RBM-007. RBM-007 is a novel nucleic acid medicine (oligonucleotide-based aptamer) developed in-house at RIBOMIC's research facilities in Tokyo. RBM-007 has been shown to have potent effects in limiting excessive interactions between fibroblast growth factors, which are known to cause achondroplasia.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
84 JPY | -1.18% | 0.00% | -22.22% |
1st Jan change | Capi. | |
---|---|---|
-22.22% | 19.76M | |
+7.52% | 113B | |
+11.38% | 106B | |
-12.64% | 22.22B | |
+0.44% | 22.27B | |
-4.18% | 19.43B | |
-37.85% | 17.87B | |
-8.58% | 17.24B | |
+37.41% | 12.52B | |
-23.95% | 8.34B |
- Stock Market
- Equities
- 4591 Stock
- News Ribomic Inc.
- RIBOMIC, Inc. Announces Start of Administration of RBM-007, Achondroplasia Investigational Drug, to the First Patient in the Early Phase II Study in Japan